Dexamethasone (DEX) was applied in neonatal respiratory
distress
syndrome treatment of pregnant women. We established a pharmacokinetics
(PK)/pharmacodynamics(PD)/end point model of pregnant animals based
on published data and then extrapolated to simulate fetal exposure
and lung maturation in pregnant women. We first established the PK/PD/end
point model for DEX in pregnant sheep. We considered the competitive
effect of cortisol (Cort) and DEX binding with glucocorticoid receptor
and then used the indirect response model to describe disaturated-phosphatidylcholine
(DSPC) dynamics. Based on that, we established a regression relationship
between DSPC and fetal lung volume (V40). We then extrapolated the
PD/end point model of pregnant sheep to pregnant monkeys by corrected
stages of morphologic lung maturation in two species. Finally, we
utilized the interspecies extrapolation strategy to simulate fetal
exposure (AUC0–48h) and V40 relationship in pregnant
women. The current model could well describe the maternal-fetal PK
of DEX in pregnant animals. Simulated DEX AUC0–24h values of the umbilical venous to maternal plasma ratio in pregnant
sheep and monkeys were 0.31 and 0.27, respectively. The simulated
Cort curve and V40 in pregnant sheep closely matched the observed
data within a 2-fold range. For pregnant monkeys, model-simulated
V40 were well fitted with external verification data, which showed
good interspecies extrapolation performance. Finally, we simulated
fetal exposure–response relationship in pregnant women, which
indicated that the fetal AUC0–48h of DEX should
not be less than 300 and 100 ng/mL·hr at GW28 and GW34 to ensure
fetal lung maturity. The current model preliminarily provided support
for clinical DEX dose optimization.